| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $468,294 | 5 | 50 |
Sells | $1,565,430 | 5 | 50 |
| Grossman Jerrold B | director | 3 | $250,874 | 0 | $0 | $250,874 |
| ELMS STEVE | director | 2 | $217,420 | 0 | $0 | $217,420 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | 0 | $0 | 1 | $157,800 | $-157,800 |
| Grossman Adam S | President and CEO | 0 | $0 | 4 | $1.41M | $-1.41M |
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company …
Over the last 12 months, insiders at ADMA Biologics, Inc. have bought $468,294 and sold $1.57M worth of ADMA Biologics, Inc. stock.
On average, over the past 5 years, insiders at ADMA Biologics, Inc. have bought $576,819 and sold $12.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Grossman Jerrold B (director) — $250,874. ELMS STEVE (director) — $217,420.
The last purchase of 6,400 shares for transaction amount of $50,624 was made by Grossman Jerrold B (director) on 2026‑05‑27.
| 2026-05-27 | Grossman Jerrold B | director | 6,400 0.0028% | $7.91 | $50,624 | +17.93% | ||
| 2026-05-12 | Grossman Jerrold B | director | 12,500 0.0051% | $8.01 | $100,125 | +9.51% | ||
| 2026-05-11 | Grossman Jerrold B | director | 12,500 0.0055% | $8.01 | $100,125 | +16.56% | ||
| 2026-03-16 | Sale | Grossman Adam S | President and CEO | 21,000 0.0084% | $15.16 | $318,360 | -40.72% | |
| 2026-03-09 | Sale | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | 10,096 0.0043% | $15.63 | $157,800 | -40.35% | |
| 2026-03-06 | ELMS STEVE | director | 7,000 0.0029% | $15.39 | $107,730 | -38.60% | ||
| 2026-03-05 | ELMS STEVE | director | 7,000 0.0029% | $15.67 | $109,690 | -39.75% | ||
| 2026-02-17 | Sale | Grossman Adam S | President and CEO | 21,000 0.0089% | $16.08 | $337,680 | -40.19% | |
| 2025-12-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0088% | $19.79 | $415,590 | -49.34% | |
| 2025-11-19 | Sale | Grossman Adam S | President and CEO | 21,000 0.0089% | $16.00 | $336,000 | -36.18% | |
| 2025-09-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0093% | $16.13 | $338,730 | -6.41% | |
| 2025-08-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0087% | $16.88 | $354,480 | -11.30% | |
| 2025-07-15 | Sale | Grossman Adam S | President and CEO | 21,000 0.0091% | $18.66 | $391,860 | -13.18% | |
| 2025-06-16 | Sale | Grossman Adam S | President and CEO | 21,000 0.009% | $20.81 | $437,010 | -21.42% | |
| 2025-06-16 | Sale | ELMS STEVE | director | 194,749 0.0809% | $20.24 | $3.94M | -21.42% | |
| 2025-06-13 | Sale | ELMS STEVE | director | 137,931 0.0578% | $20.82 | $2.87M | -22.66% | |
| 2025-06-12 | Sale | ELMS STEVE | director | 92,941 0.0391% | $21.69 | $2.02M | -25.46% | |
| 2025-06-09 | Sale | Grossman Jerrold B | director | 10,000 0.0043% | $21.31 | $213,100 | -22.62% | |
| 2025-06-09 | Sale | Guiheen Lawrence P. | director | 20,000 0.0084% | $20.96 | $419,200 | -22.62% | |
| 2025-05-22 | Sale | Guiheen Lawrence P. | director | 1,221 0.0005% | $20.12 | $24,567 | -18.70% |
| Grossman Adam S | President and CEO | 2112777 0.9433% | $23.47M | 37 | 18 | <0.0001% |
| ELMS STEVE | director | 2045730 0.9133% | $22.73M | 2 | 8 | |
| Grossman Jerrold B | director | 520284 0.2323% | $5.78M | 20 | 2 | <0.0001% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 13262375 5.9211% | $147.34M | 3 | 9 | <0.0001% |
| Aisling Capital II LP | 10 percent owner | 3620143 1.6162% | $40.22M | 1 | 0 | |
| Burrill Capital Fund IV, L.P. | 10 percent owner | 1433304 0.6399% | $15.92M | 1 | 0 | |
| LENZ BRIAN | EVP, CFO | 782013 0.3491% | $8.69M | 15 | 2 | +5.59% |
| KWON YOUNG | director | 241441 0.1078% | $2.68M | 2 | 1 | +48.43% |
| Guiheen Lawrence P. | director | 94830 0.0423% | $1.05M | 5 | 4 | <0.0001% |
| Mond James | EVP, CSO and CMO | 73174 0.0327% | $812,963.14 | 8 | 0 | +2.83% |
| RICHMAN ERIC I | director | 36530 0.0163% | $405,848.30 | 3 | 0 | +39.74% |
| DEMSKI MARTHA J | director | 4200 0.0019% | $46,662.00 | 2 | 0 | <0.0001% |
| Biotest AG | 10 percent owner | 0 0% | $0 | 1 | 1 | +103.33% |
ADMA Biologics, Inc. (ADMA) | $52,263,649 | 70 | 1.18% | $2.49B |
$586,486,795 | 47 | 4.28% | $2.38B | |
$154,047,855 | 36 | 79.21% | $2.21B | |
$28,907,358 | 35 | 41.41% | $2.28B | |
$1,603,489 | 30 | 98.90% | $2.33B |
| Increased Positions | 205 | +50.25% | 31M | +14.19% |
| Decreased Positions | 185 | -45.34% | 30M | -13.78% |
| New Positions | 61 | New | 8M | New |
| Sold Out Positions | 63 | Sold Out | 15M | Sold Out |
| Total Postitions | 428 | +4.9% | 219M | +0.41% |
| Blackrock, Inc. | $637,095.00 | 14.97% | 35.63M | -841,666 | -2.31% | 2025-09-30 |
| Vanguard Group Inc | $375,033.00 | 8.81% | 20.97M | -388,719 | -1.82% | 2025-09-30 |
| State Street Corp | $242,482.00 | 5.7% | 13.56M | +1M | +12.28% | 2025-09-30 |
| Invesco Ltd. | $223,598.00 | 5.25% | 12.51M | -312,663 | -2.44% | 2025-09-30 |
| Sachem Head Capital Management Lp | $160,205.00 | 3.77% | 8.96M | +9M | New | 2025-09-30 |
| Geode Capital Management, Llc | $103,950.00 | 2.44% | 5.81M | -99,383 | -1.68% | 2025-09-30 |
| Nuveen, Llc | $102,348.00 | 2.41% | 5.72M | +161,241 | +2.9% | 2025-09-30 |
| Westfield Capital Management Co Lp | $91,310.00 | 2.15% | 5.11M | +5M | New | 2025-09-30 |
| Dimensional Fund Advisors Lp | $85,793.00 | 2.02% | 4.8M | +35,199 | +0.74% | 2025-09-30 |
| American Century Companies Inc | $83,963.00 | 1.97% | 4.7M | +84,934 | +1.84% | 2025-09-30 |